Comparing Potassium-Competitive Acid Blocker And Proton Pump Inhibitor For Gastroeshopageal Reflux Disease: A Systematic Review And Meta-Analysis
Abstract
Clinical management is typically used to treat gastroesophageal reflux disease (GERD). Assessed individuals with a range of clinical symptoms of gastroesophageal reflux disease (GERD) to determine the safety and effectiveness of potassium-competitive acid blockers (PCABs). By examining core databases, studies comparing PCABs and proton pump inhibitors (PPIs) in clinical gastroesophageal reflux disease (GERD) and PPI-resistant GERD were identified. In nine randomized controlled trials (RCTs) evaluating the first care of GERD, the risk ratio for healing with PCABs versus PPIs was 1.09 (95% CI, 1.04-1.13) at 2 weeks and 1.03 (95% CI, 1.00-1.07) after 8 weeks, respectively. While 86.3% of PPI-resistant GERD patients reported an improvement in symptom frequency, 90.7% of patients showed improvement in five observational trials. When it comes to the initial and ongoing treatment of GERD, especially severe GERD, PCABs are more effective and have a quicker therapeutic effect than PPIs. However, PCABs might be a different kind of treatment for GERD and GERD that is resistant to PPIs.
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study
- Treatment and prognostic factors for long-term outcome in patients with anti-N-Methyl-D-Aspartate (NMDA) receptor encephalitis: a cohort study
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- Postsurgical prescriptions for opioid naive patients and association with overdose and misuse: retrospective cohort study
- Ethnic and socioeconomic differences in SARS-CoV-2 infection: prospective cohort study using UK Biobank
- Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.